Oculis Holding AG Ordinary shares (OCS) Stock
Key stats
- Market cap
- $424.00M
- Price / Earnings ratio
- -5.3x
- EPS (TTM)
- -$1.63
- Volume
- Loading
- 52-week high
- $34.48
- 52-week low
- $6.78
Source: third-party data provider, as of November 13, 2026
Compare with OCS
Recent news

Oculis Holding AG (OCS) Reports Q3 Loss, Lags Revenue Estimates
Oculis Holding AG (OCS) Reports Q3 Loss, Lags Revenue Estimates
OCS

Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
OCS

After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)
After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)
OCS

Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade
Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade
OCS
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 43.26
- MACD 12/26/9
- -0.37
- EMA 9 of MACD
- -0.45
- MACD histogram
- 0.08
- SMA 50
- $8.92
- Price below SMA 50
- EMA 50
- $8.99
- Price below EMA 50
- SMA 200
- $18.07
- Price below SMA 200
- EMA 200
- $16.23
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Oculis Holding AG (OCS) Reports Q3 Loss, Lags Revenue Estimates
Oculis Holding AG (OCS) Reports Q3 Loss, Lags Revenue Estimates
OCS

Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
OCS

After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)
After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)
OCS

Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade
Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade
OCS

Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?
OCS

Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates
OCS

OCS Group to buy Mitie for $4.17 billion
OCS Group to buy Mitie for $4.17 billion
OCS

Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
OCS

OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm
OCS

OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud
OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud
OCS
News tone: automated (AI) classification of the article's content, not a price prediction.
About Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Riad Sherif M.B.A., M.D. | CEO & Director | 1968 |
| Ms. Sylvia Cheung | Chief Financial Officer | 1975 |
| Ms. Gudrun Bachmann Ph.D. | Chief Technology Officer | — |
| Dr. Ramin Tadayoni M.D., Ph.D. | Chief Scientific Officer | — |
| Ms. Katie Kazem | Chief Legal Officer | — |
| Ms. Virginia R. Dean | Chief Human Resources Officer | 1966 |
| Mr. Páll Ragnar Jóhannesson | Chief Business Officer | 1982 |
| Ms. Rebecca Weil Ph.D. | Chief Commercial Officer | — |
| Dr. Snehal Shah Pharm.D. | President of Research & Development | — |
| Dr. Sharon Klier M.D., M.P.H. | Chief Development Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 43.26
- MACD 12/26/9
- -0.37
- EMA 9 of MACD
- -0.45
- MACD histogram
- 0.08
- SMA 50
- $8.92
- Price below SMA 50
- EMA 50
- $8.99
- Price below EMA 50
- SMA 200
- $18.07
- Price below SMA 200
- EMA 200
- $16.23
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $20.00
- Average
- $33.00
- High
- $40.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -25.3 | -4.4 | -16.4 | +3.0 | -23.3 | -5.7 | -1.3 |



